Hervycta Plus 150mg Injection is a targeted therapy used in the treatment of certain types of cancer. Its active ingredient, Trastuzumab, is a monoclonal antibody that specifically targets the HER2 (Human Epidermal growth factor Receptor 2) protein. In some cancers, particularly breast and gastric cancers, cancer cells produce too much HER2 protein, which can lead to aggressive tumor growth. Hervycta Plus works by binding to these HER2-positive cancer cells, blocking the signals that promote their growth and survival. It can also flag these cancer cells for destruction by the body’s immune system.
Hervycta Plus 150mg Injection is indicated for the treatment of HER2-positive breast cancer (early and metastatic) and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The dosage and duration of treatment are determined by a qualified healthcare professional based on the patient’s condition and response to therapy. Common side effects may include infusion-related reactions, fatigue, nausea, vomiting, and diarrhea. Less common but serious side effects can include heart problems and lung issues. It is crucial to discuss potential risks and benefits with your doctor. Hervycta Plus 150mg Injection should be stored as per the manufacturer’s instructions, typically refrigerated and protected from light.
